{"DataElement":{"publicId":"7611101","version":"1","preferredName":"Metastatic Prostate Cancer Type","preferredDefinition":"Text term representing the kind of metastatic prostate cancer.","longName":"MET_PCA_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"7611090","version":"1","preferredName":"Metastatic Prostate Carcinoma Present","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Being or existing in a specified place or at the specified time.","longName":"7611088v1.0:2233878v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"7611088","version":"1","preferredName":"Metastatic Prostate Carcinoma","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.:One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","longName":"C14174:C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE37A54C-344F-625A-E053-4EBD850A6C38","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"ONEDATA","dateModified":"2021-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233878","version":"1","preferredName":"Present","preferredDefinition":"Being or existing in a specified place or at the specified time.","longName":"C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F970CDF6-F829-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE37A54C-345D-625A-E053-4EBD850A6C38","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"COOPERM","dateModified":"2021-03-23","changeDescription":"Created for NCI-INC0567536 21C0001 metastatic prostate cancer request. 3.23.21 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7611095","version":"1","preferredName":"Metastatic Prostate Cancer Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"MPCA_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"mCRPC","valueDescription":"Castration-Resistant Prostate Carcinoma","ValueMeaning":{"publicId":"7611096","version":"1","preferredName":"Castration-Resistant Prostate Carcinoma","longName":"7611096","preferredDefinition":"Prostate carcinoma that grows and continues to spread despite the surgical removal of the testes or medical intervention to block androgen production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Castration-Resistant Prostate Carcinoma","conceptCode":"C130234","definition":"Prostate carcinoma that grows and continues to spread despite the surgical removal of the testes or medical intervention to block androgen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE352B8B-EF14-6255-E053-4EBD850A3ECA","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"ONEDATA","dateModified":"2021-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE352B8B-EF2D-6255-E053-4EBD850A3ECA","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"ONEDATA","dateModified":"2021-03-23","deletedIndicator":"No"},{"value":"mCSPC","valueDescription":"Castration-Sensitive Prostate Carcinoma","ValueMeaning":{"publicId":"7611098","version":"1","preferredName":"Castration-Sensitive Prostate Carcinoma","longName":"7611098","preferredDefinition":"Metastatic prostatic carcinoma which is sensitive to androgen-deprivation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Castration-Sensitive Prostate Carcinoma","conceptCode":"C153336","definition":"Metastatic prostatic carcinoma which is sensitive to androgen-deprivation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE352B8B-EF3A-6255-E053-4EBD850A3ECA","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"ONEDATA","dateModified":"2021-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE352B8B-EF53-6255-E053-4EBD850A3ECA","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"ONEDATA","dateModified":"2021-03-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE352B8B-EEFE-6255-E053-4EBD850A3ECA","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"COOPERM","dateModified":"2021-03-23","changeDescription":"Created for NCI-INC0567536 21C0001 metastatic prostate cancer request. 3.23.21 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Metastatic prostate cancer","type":"Preferred Question Text","description":"Metastatic prostate cancer","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE37A54C-34A0-625A-E053-4EBD850A6C38","latestVersionIndicator":"Yes","beginDate":"2021-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-23","modifiedBy":"COOPERM","dateModified":"2021-03-23","changeDescription":"Created for NCI-INC0567536 21C0001 metastatic prostate cancer request. mc 3.23.21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}